BR9712248B1 - antagonistas receptores de vitronectina. - Google Patents

antagonistas receptores de vitronectina.

Info

Publication number
BR9712248B1
BR9712248B1 BRPI9712248-3A BR9712248A BR9712248B1 BR 9712248 B1 BR9712248 B1 BR 9712248B1 BR 9712248 A BR9712248 A BR 9712248A BR 9712248 B1 BR9712248 B1 BR 9712248B1
Authority
BR
Brazil
Prior art keywords
receptor antagonists
vitronectin receptor
vitronectin
antagonists
receptor
Prior art date
Application number
BRPI9712248-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9712248A (pt
Inventor
James Francis Callahan
Russell Donovan Cousins
Richard Mccullock Keenan
Chet Kwon
William Henry Miller
Irene Nijole Uzinkas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR9712248A publication Critical patent/BR9712248A/pt
Publication of BR9712248B1 publication Critical patent/BR9712248B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI9712248-3A 1996-10-02 1997-10-01 antagonistas receptores de vitronectina. BR9712248B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2732096P 1996-10-02 1996-10-02
US4377697P 1997-04-11 1997-04-11
PCT/US1997/018001 WO1998014192A1 (en) 1996-10-02 1997-10-01 Vitronectin receptor antagonists

Publications (2)

Publication Number Publication Date
BR9712248A BR9712248A (pt) 1999-08-24
BR9712248B1 true BR9712248B1 (pt) 2010-06-29

Family

ID=26702318

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9712248-3A BR9712248B1 (pt) 1996-10-02 1997-10-01 antagonistas receptores de vitronectina.

Country Status (36)

Country Link
EP (1) EP0957917B1 (enExample)
JP (2) JP4491072B2 (enExample)
KR (1) KR100589578B1 (enExample)
CN (1) CN1114403C (enExample)
AP (1) AP1463A (enExample)
AR (1) AR008878A1 (enExample)
AT (1) ATE312089T1 (enExample)
AU (1) AU733417B2 (enExample)
BG (1) BG64581B1 (enExample)
BR (1) BR9712248B1 (enExample)
CA (1) CA2267224C (enExample)
CO (1) CO4900046A1 (enExample)
CY (1) CY2576B1 (enExample)
CZ (1) CZ299076B6 (enExample)
DE (1) DE69734833T2 (enExample)
DK (1) DK0957917T3 (enExample)
DZ (1) DZ2320A1 (enExample)
EA (1) EA002419B1 (enExample)
ES (1) ES2252775T3 (enExample)
HU (1) HU229221B1 (enExample)
ID (1) ID19623A (enExample)
IL (1) IL129243A (enExample)
MA (1) MA24361A1 (enExample)
MY (1) MY137606A (enExample)
NO (1) NO320194B1 (enExample)
NZ (1) NZ334953A (enExample)
PE (1) PE10499A1 (enExample)
PL (1) PL190859B1 (enExample)
RO (1) RO119881B1 (enExample)
SA (1) SA98180936B1 (enExample)
SK (1) SK285029B6 (enExample)
TR (1) TR199900737T2 (enExample)
TW (1) TW487702B (enExample)
UA (1) UA60311C2 (enExample)
UY (2) UY24735A1 (enExample)
WO (1) WO1998014192A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
IL135189A0 (en) * 1997-09-24 2001-05-20 Smithkline Beecham Corp Vitronectin receptor antagonist
JP2002500162A (ja) * 1997-09-24 2002-01-08 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
US6372719B1 (en) * 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
WO2000038715A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
EP1150965A4 (en) * 1999-02-03 2002-05-15 Merck & Co Inc BENZAZEPINE DERIVATIVES AS ALPHA-V INTGRIN RECEPTOR ANTAGONISTS
MXPA01011052A (es) * 1999-04-30 2002-11-22 Univ Michigan Aplicaciones terapeuticas de benzodiazepinas pro-apoctoticas.
JP2003506452A (ja) * 1999-08-06 2003-02-18 スミスクライン・ビーチャム・コーポレイション 発作の治療に有用なビトロネクチン受容体アンタゴニスト
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE10027514A1 (de) * 2000-06-06 2002-01-03 Basf Ag Liganden von Integrinrezeptoren
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002060438A1 (en) 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
CN1248692C (zh) * 2001-04-10 2006-04-05 史密丝克莱恩比彻姆公司 玻璃体结合蛋白受体拮抗剂在制备用于抑制粘连形成的药物中的用途
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
EP1387688A2 (en) * 2001-05-03 2004-02-11 Merck & Co., Inc. Benzazepinone alpha v integrin receptor antagonists
KR20040058229A (ko) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
WO2004089890A2 (en) * 2003-04-04 2004-10-21 Smithkline Beecham Corporation Process and intermediates for preparing benzazepines
EP1734996B1 (en) * 2004-04-02 2013-05-22 The Regents of The University of California Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
TW200635902A (en) * 2004-12-21 2006-10-16 Smithkline Beecham Corp Methods and formulations
EP1968594B1 (en) * 2005-11-29 2010-09-29 GlaxoSmithKline LLC Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
EP2221308B1 (en) * 2007-11-16 2013-07-10 Ube Industries, Ltd. Benzazepinone compound
US8076475B2 (en) * 2008-03-06 2011-12-13 Glaxosmithkline Llc Process
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
EP2415474B1 (en) * 2009-03-30 2013-08-28 Ube Industries, Ltd. Pharmaceutical composition for treatment or prevention of ophthalmic diseases
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
JP5755647B2 (ja) 2009-07-24 2015-07-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア αvβ5インテグリンに関連する疾患の処置および予防のための方法および組成物
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
EP2325194A1 (en) * 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
BR112022021228A2 (pt) * 2020-04-26 2022-12-06 Jiangsu Nhwa Pharmaceutical Co Ltd Derivado da 1,5-di-hidro-2,4-benzodiazepin-3-ona e aplicação do mesmo
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236882T1 (de) * 1992-12-21 2003-04-15 Smithkline Beecham Corp Bicyklische fibrinogen antagoniste
ZA955391B (en) * 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
WO1996000730A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
JPH10504825A (ja) * 1994-08-22 1998-05-12 スミスクライン・ビーチャム・コーポレイション 二環式化合物
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Also Published As

Publication number Publication date
UY24735A1 (es) 1998-03-30
JP2010006838A (ja) 2010-01-14
CA2267224A1 (en) 1998-04-09
NO320194B1 (no) 2005-11-14
SK42599A3 (en) 1999-12-10
UA60311C2 (uk) 2003-10-15
CY2576B1 (en) 2008-07-02
SA98180936B1 (ar) 2006-05-30
EA002419B1 (ru) 2002-04-25
AU733417B2 (en) 2001-05-17
JP4491072B2 (ja) 2010-06-30
PL332674A1 (en) 1999-09-27
AU4746297A (en) 1998-04-24
DK0957917T3 (da) 2006-04-18
CN1238689A (zh) 1999-12-15
EA199900356A1 (ru) 2000-02-28
DZ2320A1 (fr) 2002-12-28
EP0957917A4 (en) 2002-05-15
ES2252775T3 (es) 2006-05-16
AP9901493A0 (en) 1999-03-31
CN1114403C (zh) 2003-07-16
TR199900737T2 (xx) 1999-07-21
AP1463A (en) 2005-09-10
CO4900046A1 (es) 2000-03-27
ATE312089T1 (de) 2005-12-15
HU229221B1 (en) 2013-09-30
CZ113299A3 (cs) 2000-03-15
BR9712248A (pt) 1999-08-24
EP0957917B1 (en) 2005-12-07
ID19623A (id) 1998-07-23
MA24361A1 (fr) 1998-07-01
WO1998014192A1 (en) 1998-04-09
IL129243A (en) 2004-07-25
CZ299076B6 (cs) 2008-04-16
KR100589578B1 (ko) 2006-06-15
DE69734833T2 (de) 2006-07-13
AR008878A1 (es) 2000-02-23
JP2001501936A (ja) 2001-02-13
NO991590L (no) 1999-05-31
NO991590D0 (no) 1999-03-31
CA2267224C (en) 2007-03-13
PL190859B1 (pl) 2006-02-28
MY137606A (en) 2009-02-27
BG64581B1 (bg) 2005-08-31
HK1023730A1 (en) 2000-09-22
PE10499A1 (es) 1999-03-27
RO119881B1 (ro) 2005-05-30
UY24935A1 (es) 2001-07-31
BG103299A (en) 2000-01-31
IL129243A0 (en) 2000-02-17
DE69734833D1 (de) 2006-01-12
SK285029B6 (sk) 2006-04-06
HUP9903769A2 (hu) 2000-03-28
KR20000048816A (ko) 2000-07-25
TW487702B (en) 2002-05-21
HUP9903769A3 (en) 2000-07-28
EP0957917A1 (en) 1999-11-24
NZ334953A (en) 2000-01-28

Similar Documents

Publication Publication Date Title
DZ2320A1 (fr) Antagonistes de récepteurs de vitronectine.
BR9508178A (pt) Antagonistas de receptor de vitronectina
BR9612327A (pt) Antagonistas receptores de vitronectina
BR9612378A (pt) Antagonistas receptores de vitronectina
TR199801594A3 (tr) CCR-3 reseptör antagonistleri.
BR9612381A (pt) Antagonistas receptores vitronectina
BR9709952A (pt) Antagonistas de receptor de il-8
NO986109D0 (no) IL-8 reseptor-antagonister
DE69812096D1 (de) Neuropeptid y rezeptorantagonisten
NO972016D0 (no) Indolyl-Y-reseptorantagonister
NO993350D0 (no) Vitronectin-reseptor-antagonister
EP0885205A4 (en) Fibrinogen Receptor Antagonists
EP0810994A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS
BR9711140A (pt) Antagonistas receptores de il-8
TR199600359A2 (tr) Adezyon reseptörü antagonistleri.
ID24726A (id) Antagonis-antagonis reseptor trombin
DK0906294T3 (da) Benzoxazinon-dopamin D4-receptor-antagonister
NO20004503L (no) Vitronectin-reseptor-antagonister
EP0684823A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS.
NO20001407D0 (no) Vitronectin-reseptor-antagonister
NO20001514D0 (no) Vitronectin-reseptor-antagonist
NO20001515D0 (no) Vitronektin reseptor-antagonist
TR199501389A2 (tr) Adesyon reseptörü antagonistleri (karsitlari).
DZ2322A1 (fr) Antagonistes de récepteurs de vitronectine.
BR9507220A (pt) Antagonistas de receptores de endotelina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/06/2010, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved

Owner name: GLAXOSMITHKLINE LLC (US)

Free format text: NOME ALTERADO DE: SMITHKLINE BEECHAM CORPORATION

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE. PAGAR RESTAURACAO.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 21.6 PUBLICADO NA RPI 2343 DE 01/12/2015.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)